PDCD1 and melanoma: However, differences could also be related to different settings and that the present study mainly included non‐small cell lung cancer patients treated with PD‐1 immune checkpoint inhibitors, while for example, Del Castillo and colleagues7 included melanoma patients mainly treated with cytotoxic T‐lymphocyte antigen 4 immune checkpoint inhibitors.